Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

June 13, 2019

Study Completion Date

July 9, 2019

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

BION-1301

a solution for intravenous (IV) administration, diluted and administered Q2W

Trial Locations (7)

15232

UPMC (University of Pittsburgh Medical Center) Hillman Cancer Center, Pittsburgh

22031

Virginia Cancer Specialists, Fairfax

30322

Winship Cancer Institute/Emory University, Atlanta

43210

Ohio State University Wexner Medical Center James Cancer Hospital, Columbus

53226

Froedtert Hospital & The Medical College of Wisconsin, Milwaukee

90069

James R. Berenson, MD, Inc, West Hollywood

98104

Swedish Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Chinook Therapeutics, Inc.

INDUSTRY